Regulation of fear extinction versus other affective behaviors by discrete cortical scaffolding complexes associated with NR2B and PKA signaling

Translational Psychiatry

Volumn 5, Issue 10, 2015, Pages

  Corcoran, K A ^a   Leaderbrand, K ^a   Jovasevic, V ^a   Guedea, A L ^a   Kassam, F ^a   Radulovic, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; MULTIPROTEIN COMPLEX; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; RECEPTOR FOR ACTIVATED C KINASE 1; SCAFFOLD PROTEIN; TRANSACTIVATOR PROTEIN; ANTIDEPRESSANT AGENT; DIZOCILPINE MALEATE; GNB2-RS1 PROTEIN, MOUSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE; NR2B PROTEIN (1292-1308); PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EMOTIONALITY; EXON; FEAR; INTRACELLULAR SIGNALING; LATENT PERIOD; LONG TERM MEMORY; MALE; MOUSE; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RETROSPLENIAL CORTEX; ANIMAL; BEHAVIOR; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; PHYSIOLOGY; REINFORCEMENT; SIGNAL TRANSDUCTION; STRESS DISORDERS, POST-TRAUMATIC;

A KINASE ANCHOR PROTEINS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIORAL SYMPTOMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXTINCTION, PSYCHOLOGICAL; FEAR; HIPPOCAMPUS; MICE; NEUROPEPTIDES; PEPTIDE FRAGMENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84990879558     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.150     Document Type: Article

References (76)

1. Yehuda R, McFarlane AC, Shalev AY. Predicting the development of posttraumatic stress disorder from the acute response to a traumatic event. Biol Psychiatry 1998; 44: 1305-1313.
2. Otto MW, Perlman CA, Wernicke R, Reese HE, Bauer MS, Pollack MH. Posttraumatic stress disorder in patients with bipolar disorder: A review of prevalence, correlates, and treatment strategies. Bipolar Disord 2004; 6: 470-479.
3. Associa AP. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Publishing: Arlington, VA, USA, 2013.
4. Davidson JR. Trauma: The impact of post-Traumatic stress disorder. J Psychopharmacol 2000; 14: S5-12.
5. Rytwinski NK, Avena JS, Echiverri-Cohen AM, Zoellner LA, Feeny NC. The relationships between posttraumatic stress disorder severity, depression severity and physical health. J Health Psychol 2014; 19: 509-520.
6. Campbell DG, Felker BL, Liu CF, Yano EM, Kirchner JE, Chan D et al. Prevalence of depression-PTSD comorbidity: Implications for clinical practice guidelines and primary care-based interventions. J Gen Intern Med 2007; 22: 711-718.
7. O'Donnell ML, Creamer M, Pattison P. Posttraumatic stress disorder and depression following trauma: Understanding comorbidity. Am J Psychiatry 2004; 161: 1390-1396.
8. Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do? Nat Rev Neurosci 2009; 10: 792-802.
9. Piefke M, Pestinger M, Arin T, Kohl B, Kastrau F, Schnitker R et al. The neurofunctional mechanisms of traumatic and non-Traumatic memory in patients with acute PTSD following accident trauma. Neurocase 2007; 13: 342-357.
10. Lanius RA, Bluhm RL, Coupland NJ, Hegadoren KM, Rowe B, Theberge J et al. Default mode network connectivity as a predictor of post-Traumatic stress disorder symptom severity in acutely traumatized subjects. Acta Psychiatr Scand 2010; 121: 33-40.
11. Daniels JK, Frewen P, McKinnon MC, Lanius RA. Default mode alterations in posttraumatic stress disorder related to early-life trauma: A developmental perspective. J Psychiatry Neurosci 2011; 36: 56-59.
12. Eckart C, Stoppel C, Kaufmann J, Tempelmann C, Hinrichs H, Elbert T et al. Structural alterations in lateral prefrontal, parietal and posterior midline regions of men with chronic posttraumatic stress disorder. J Psychiatry Neurosci 2011; 36: 176-186.
13. Sartory G, Cwik J, Knuppertz H, Schurholt B, Lebens M, Seitz RJ et al. In search of the trauma memory: A meta-Analysis of functional neuroimaging studies of symptom provocation in posttraumatic stress disorder (PTSD). PLoS One 2013; 8: E58150.
14. Kumar P, Waiter G, Ahearn T, Milders M, Reid I, Steele JD. Abnormal temporal difference reward-learning signals in major depression. Brain 2008; 131: 2084-2093.
15. Zhu X, Wang X, Xiao J, Liao J, Zhong M, Wang W et al. Evidence of a dissociation pattern in resting-state default mode network connectivity in first-episode, treatment-naive major depression patients. Biol Psychiatry 2012; 71: 611-617.
16. Corcoran KA, Donnan MD, Tronson NC, Guzman YF, Gao C, Jovasevic V et al. NMDA receptors in retrosplenial cortex are necessary for retrieval of recent and remote context fear memory. J Neurosci 2011; 31: 11655-11659.
17. Corcoran KA, Leaderbrand K, Radulovic J. Extinction of remotely acquired fear depends on an inhibitory NR2B/PKA pathway in the retrosplenial cortex. J Neurosci 2013; 33: 19492-19498.
18. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M et al. Genetic enhancement of learning and memory in mice. Nature 1999; 401: 63-69.
19. Isiegas C, Park A, Kandel ER, Abel T, Lattal KM. Transgenic inhibition of neuronal protein kinase A activity facilitates fear extinction. J Neurosci 2006; 26: 12700-12707.
20. Quirk GJ, Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008; 33: 56-72.
21. Lin CH, Yeh SH, Lu HY, Gean PW. The similarities and diversities of signal pathways leading to consolidation of conditioning and consolidation of extinction of fear memory. J Neurosci 2003; 23: 8310-8317.
22. Maren S, Quirk GJ. Neuronal signalling of fear memory. Nat Rev Neurosci 2004; 5: 844-852.
23. Kim JJ, Fanselow MS. Modality-specific retrograde amnesia of fear. Science 1992; 256: 675-677.
24. Frankland PW, Bontempi B. The organization of recent and remote memories. Nat Rev Neurosci 2005; 6: 119-130.
25. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
26. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
27. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alphaamino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-352.
28. Kiselycznyk C, Svenningsson P, Delpire E, Holmes A. Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm. Neuroscience 2011; 193: 259-268.
29. Burghardt NS, Sigurdsson T, Gorman JM, McEwen BS, Ledoux JE. Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry 2013; 73: 1078-1086.
30. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. Proteomic analysis of NMDA receptor-Adhesion protein signaling complexes. Nat Neurosci 2000; 3: 661-669.
31. Migaud M, Charlesworth P, Dempster M, Webster LC, Watabe AM, Makhinson M et al. Enhanced long-Term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 1998; 396: 433-439.
32. Gao C, Frausto SF, Guedea AL, Tronson NC, Jovasevic V, Leaderbrand K et al. IQGAP1 regulates NR2A signaling, spine density, and cognitive processes. J Neurosci 2011; 31: 8533-8542.
33. Gao C TN, Radulovic J. Modulation of behavior by scaffolding proteins of the postsynaptic density. Neurobiol Learn Mem 2013; 105: 3-12.
34. Yaka R, Thornton C, Vagts AJ, Phamluong K, Bonci A, Ron D. NMDA receptor function is regulated by the inhibitory scaffolding protein, RACK1. Proc Natl Acad Sci USA 2002; 99: 5710-5715.
35. Rubino HM, Dammerman M, Shafit-Zagardo B, Erlichman J. Localization and characterization of the binding site for the regulatory subunit of type II cAMPdependent protein kinase on MAP2. Neuron 1989; 3: 631-638.
36. Smith KE, Gibson ES, Dell'Acqua ML. cAMP-dependent protein kinase postsynaptic localization regulated by NMDA receptor activation through translocation of an A-kinase anchoring protein scaffold protein. J Neurosci 2006; 26: 2391-2402.
37. Harada A, Teng J, Takei Y, Oguchi K, Hirokawa N. MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. J Cell Biol 2002; 158: 541-549.
38. Tunquist BJ, Hoshi N, Guire ES, Zhang F, Mullendorff K, Langeberg LK et al. Loss of AKAP150 perturbs distinct neuronal processes in mice. Proc Natl Acad Sci USA 2008; 105: 12557-12562.
39. Weisenhaus M, Allen ML, Yang L, Lu Y, Nichols CB, Su T et al. Mutations in AKAP5 disrupt dendritic signaling complexes and lead to electrophysiological and behavioral phenotypes in mice. PLoS One 2010; 5: E10325.
40. Kapitein LC, Yau KW, Gouveia SM, van der Zwan WA, Wulf PS, Keijzer N et al. NMDA receptor activation suppresses microtubule growth and spine entry. J Neurosci 2011; 31: 8194-8209.
41. Zhong H, Sia GM, Sato TR, Gray NW, Mao T, Khuchua Z, Huganir RL, Svoboda K. Subcellular dynamics of type II PKA in neurons. Neuron 2009; 62: 363-374.
42. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F. Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: A tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci USA 2002; 99: 4489-4494.
43. Bellone C, Luscher C. Cocaine triggered AMPA receptor redistribution is reversed in vivo by mGluR-dependent long-Term depression. Nat Neurosci 2006; 9: 636-641.
44. Yang L, Mao L, Tang Q, Samdani S, Liu Z, Wang JQ. A novel Ca2+-independent signaling pathway to extracellular signal-regulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons. J Neurosci 2004; 24: 10846-10857.
45. Faruque OM, Le-Nguyen D, Lajoix AD, Vives E, Petit P, Bataille D et al. Cellpermeable peptide-based disruption of endogenous PKA-AKAP complexes: A tool for studying the molecular roles of AKAP-mediated PKA subcellular anchoring. Am J Physiol Cell Physiol 2009; 296: C306-C316.
46. Tadic A, Wagner S, Schlicht KF, Peetz D, Borysenko L, Dreimuller N et al. The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 415-420.
47. Dreimuller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C et al. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology 2012; 62: 264-269.
48. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
49. Chiaruttini C, Sonego M, Baj G, Simonato M, Tongiorgi E. BDNF mRNA splice variants display activity-dependent targeting to distinct hippocampal laminae. Mol Cell Neurosci 2008; 37: 11-19.
50. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009; 66: 488-497.
51. Baj G, Del Turco D, Schlaudraff J, Torelli L, Deller T, Tongiorgi E. Regulation of the spatial code for BDNF mRNA isoforms in the rat hippocampus following pilocarpine-Treatment: A systematic analysis using laser microdissection and quantitative real-Time PCR. Hippocampus 2013; 23: 413-423.
52. Luoni A, Hulsken S, Cazzaniga G, Racagni G, Homberg JR, Riva MA. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int J Neuropsychopharmacol 2013; 16: 1319-1330.
53. Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki S, Ozaki N et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One 2011; 6: E23881.
54. Gold MG, Fowler DM, Means CK, Pawson CT, Stephany JJ, Langeberg LK et al. Engineering AKAP-selective regulatory subunits of PKA through structure-based phage selection. J Biol Chem 2013; 288: 17111-17121.
55. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95.
56. Guzman YF, Tronson NC, Jovasevic V, Sato K, Guedea AL, Mizukami H et al. Fear-enhancing effects of septal oxytocin receptors. Nat Neurosci 2013; 16: 1185-1187.
57. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35-41.
58. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809.
59. Tronson NC, Schrick C, Fischer A, Sananbenesi F, Pages G, Pouyssegur J et al. Regulatory mechanisms of fear extinction and depression-like behavior. Neuropsychopharmacology 2008; 33: 1570-1583.
60. Myers KM, Davis M. Behavioral and neural analysis of extinction. Neuron 2002; 36: 567-584.
61. Andrus BM, Blizinsky K, Vedell PT, Dennis K, Shukla PK, Schaffer DJ et al. Gene expression patterns in the hippocampus and amygdala of endogenous depression and chronic stress models. Mol Psychiatry 2012; 17: 49-61.
62. Lopez J, Vasconcelos AP, Cassel JC. Differential sensitivity of recent vs. remote memory traces to extinction in a water-maze task in rats. Neurobiol Learn Mem 2008; 90: 460-466.
63. Inda MC, Muravieva EV, Alberini CM. Memory retrieval and the passage of time: From reconsolidation and strengthening to extinction. J Neurosci 2011; 31: 1635-1643.
64. Graff J, Joseph NF, Horn ME, Samiei A, Meng J, Seo J et al. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 2014; 156: 261-276.
65. Sotres-Bayon F, Bush DE, LeDoux JE. Acquisition of fear extinction requires activation of NR2B-containing NMDA receptors in the lateral amygdala. Neuropsychopharmacology 2007; 32: 1929-1940.
66. Dalton GL, Wu DC, Wang YT, Floresco SB, Phillips AG. NMDA GluN2A and GluN2B receptors play separate roles in the induction of LTP and LTD in the amygdala and in the acquisition and extinction of conditioned fear. Neuropharmacology 2012; 62: 797-806.
67. Krystal JH. N-methyl-D-Aspartate glutamate receptor antagonists and the promise of rapid-Acting antidepressants. Arch Gen Psychiatry 2010; 67: 1110-1111.
68. Shabel SJ, Proulx CD, Piriz J, Malinow R. Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment. Science 2014; 345: 1494-1498.
69. Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N. Identification of the cortical neurons that mediate antidepressant responses. Cell 2012; 149: 1152-1163.
70. Shelton RC, Hal Manier D, Lewis DA. Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls. Int J Neuropsychopharmacol 2009; 12: 1223-1232.
71. Jurado S, Biou V, Malenka RC. A calcineurin/AKAP complex is required for NMDA receptor-dependent long-Term depression. Nat Neurosci 2010; 13: 1053-1055.
72. Crozatier C, Farley S, Mansuy IM, Dumas S, Giros B, Tzavara ET. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience 2007; 144: 1470-1476.
73. Zhu WL, Shi HS, Wang SJ, Wu P, Ding ZB, Lu L. Hippocampal CA3 calcineurin activity participates in depressive-like behavior in rats. J Neurochem 2011; 117: 1075-1086.
74. Castren E, da Penha Berzaghi M, Lindholm D, Thoenen H. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp Neurol 1993; 122: 244-252.
75. Matsuki H, Shirayama Y, Hashimoto K, Tanaka A, Minabe Y. Effects of age and gender on the expression of brain-derived neurotrophic factor mRNA in rat retrosplenial cortex following administration of dizocilpine. Neuropsychopharmacology 2001; 25: 258-266.
76. Otvos L Jr. Peptide-based drug design: Here and now. Methods Mol Biol 2008; 494: 1-8.